[1] Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78 (9): 1151-1159. [2] 黄德晖, 吴卫平, 胡学强. 中国视神经脊髓炎谱系疾病诊断与治疗指南(2021版)[J]. 中国神经免疫学和神经病学杂志, 2021, 28(6): 423-436. [3] Cruz R A, Chaudhary S, Guevara M, et al. Neuromyelitis optica spectrum disorders (nmosd) and connective tissue disease (CTD): an Update for the Rheumatologist[J]. Curr Rheumatol Rep, 2021, 23 (6): 33. [4] Esposito J E, Annoni G, D'Amato M, et al. Systemic connective tissue disease and neuromyelitis optica spectrum disorder coexistence: a systematic review and meta-analysis[J]. J Integr Neurosci, 2024, 23 (2): 35. [5] Kopp C R, Prasad C B, Naidu S, et al. Overlap syndrome of anti-aquaporin-4 positive neuromyelitis optica spectrum disorder and systemic lupus erythematosus: a systematic review of individual patient data[J]. Lupus, 2023, 32 (10): 1164-1172. [6] Mealy M A, Wingerchuk D M, Greenberg B M, et al. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis[J]. Arch Neurol, 2012, 69 (9): 1176-1180. [7] Abou Raya A, Raya S A. Neuromyelitis optica spectrum disorders (NMOSD) and systemic lupus erythematosus (SLE): Dangerous duo[J]. Int J Rheum Dis, 2024, 27 (1): e14973. [8] 中华医学会神经病学分会神经免疫学组. 中国重症肌无力诊断和治疗指南(2025版)[J]. 中华神经科杂志,2025, 58 (7): 721-741. [9] Zhu Y, Wang B, Hao Y, et al. Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases[J]. Front Immunol, 2023, 14 1223322. [10] Leite M I, Coutinho E, Lana-Peixoto M, et al. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients[J]. Neurology, 2012, 78 (20): 1601-1607. [11] Wang Z, Yan Y. Immunopathogenesis in myasthenia gravis and neuromyelitis optica[J]. Front Immunol, 2017, 8:1785. [12] Hrycek A. Systemic lupus erythematosus and myasthenia gravis[J]. Pol Arch Med Wewn, 2009, 119 (9): 582-585. [13] Minchenberg S B, Chaparala G, Oaks Z, et al. Systemic lupus erythematosus-myasthenia gravis overlap syndrome: presentation and treatment depend on prior thymectomy[J]. Clin Immunol, 2018, 194:100-104. [14] Jallouli M, Saadoun D, Eymard B, et al. The association of systemic lupus erythematosus and myasthenia gravis: a series of 17 cases, with a special focus on hydroxychloroquine use and a review of the literature[J]. J Neurol, 2012, 259 (7): 1290-1297. [15] Ali M, Riad M, Adhikari P, et al. Association between myasthenia gravis and systemic lupus erythematosus as a comorbid state[J]. Cureus, 2021, 13 (4): e14719. [16] Raut S, Reddy I, Sahi F M, et al. Association between systemic lupus erythematosus and myasthenia gravis: coincidence or sequelae?[J]. Cureus, 2020, 12 (6): e8422. [17] Ganesh A. Practice current: how do you treat neuromyelitis optica?[J]. Neurol Clin Pract, 2017, 7 (2): 170-178. [18] Bonnan M, Valentino R, Debeugny S, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders[J]. J Neurol Neurosurg Psychiatry, 2018, 89 (4): 346-351. [19] Narayanaswami P, Sanders D B, Wolfe G, et al. International consensus guidance for management of Myasthenia Gravis: 2020 Update[J]. Neurology, 2021, 96 (3): 114-122. [20] Brittain G, Roldan E, Alexander T, et al. The role of chimeric antigen receptor T-Cell therapy in immune-mediated neurological diseases[J]. Ann Neurol, 2024, 96 (3): 441-452. [21] Cojocaru M, Cojocaru I M, Silosi I. Multiple autoimmune syndrome[J]. Maedica (Bucur), 2010, 5(2): 132-134.
PDF(1243 KB)
